DexCom (DXCM)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
At a market value of $39.2B, DexCom's free cash flow of $1.1B (fiscal 2025) would need to grow about 13% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.
Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from DexCom's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.
Fundamental grade
Five factors scored 1 to 9 from DXCM's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from DexCom's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Net income | $217M | $341M | $542M | $576M | $836M |
| Free cash flow | $53M | $305M | $512M | $631M | $1.1B |
| EPS (diluted) | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
| Operating margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
Where the revenue comes from
Revenue by regions, fiscal 2025.
Superinvestors who own DXCM
From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $218M | 0.08% | Q2 2026 |
| Ron Baron Baron Capital (BAMCO) |
Added | $17M | 0.02% | Q2 2026 |
| PRIMECAP Management PRIMECAP Management Co |
New position | $13M | 0.01% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | $7M | 0.02% | Q2 2026 |
| Mario Gabelli GAMCO Investors |
Trimmed | $4M | 0.03% | Q2 2026 |
Insider buying
Open-market purchases by DexCom's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 17, 2026 | Ro Khanna |
0 | $70.43 | — |
| Feb 17, 2026 | Ro Khanna |
0 | $70.43 | — |
| Feb 17, 2026 | Ro Khanna |
0 | $70.43 | — |
| Jan 29, 2026 | Ro Khanna |
0 | $74.00 | — |
| Jan 29, 2026 | Ro Khanna |
0 | $74.00 | — |
| Jan 29, 2026 | Ro Khanna |
0 | $74.00 | — |
| Jan 26, 2026 | John Boozman |
0 | $73.34 | — |
| Jan 26, 2026 | John Boozman |
0 | $73.34 | — |
| Jan 26, 2026 | John Boozman |
0 | $73.34 | — |
| Nov 10, 2025 | Jacob Steven Leach |
18,200 | $55.04 | $1M |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when DXCM trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
What growth does DexCom's stock price imply?
At a market value of $39.2B, DexCom would need its free cash flow to grow about 13% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 135% a year.
Are DexCom insiders buying the stock?
10 open-market insider purchases of DXCM in the last 12 months, from SEC Form 4 filings.
Which superinvestors own DexCom?
5 of the superinvestors Investingly tracks hold DXCM in their latest 13F, including Cliff Asness, Ron Baron, PRIMECAP Management.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.